Allakos Inc. (ALLK) News
Filter ALLK News Items
ALLK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ALLK News From Around the Web
Below are the latest news stories about ALLAKOS INC that investors may wish to consider to help them evaluate ALLK as an investment opportunity.
3 US Penny Stocks Under $200M Market Cap To WatchAs the U.S. stock market experiences fluctuations, with technology shares recently sliding and major indices taking a breather from their record highs, investors are on the lookout for new opportunities. Penny stocks, often representing smaller or newer companies, might seem like a term from bygone trading days but continue to hold relevance due to their potential for growth when backed by strong fundamentals. This article will explore three such penny stocks that stand out for their... |
All You Need to Know About Allakos (ALLK) Rating Upgrade to BuyAllakos (ALLK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Allakos Provides Business Update and Reports Third Quarter 2024 Financial ResultsSAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2024. Recent Allakos Events Reported safety, pharmacokinetics (PK), and pharmacodynamic (PD) results from the Phase 1 trial of subcutaneous (SC) AK006 in healthy volunteers. Bio |
3 US Penny Stocks With Market Caps Larger Than $50MAs investors digest a flurry of earnings reports, stock futures are pointing to a lower open for major U.S. indexes, reflecting the ongoing volatility and mixed sentiment in the market. For those exploring investment opportunities beyond the traditional large-cap stocks, penny stocks—despite their somewhat outdated name—remain an intriguing area due to their potential for growth and value. In this article, we examine several penny stocks that exhibit strong financial foundations, offering... |
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– Top-line Phase 1 results of Intravenous AK006 in patients with CSU are expected in early Q1 of 2025 – SAN CARLOS, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced results fr |
Allakos Provides Business Update and Reports Second Quarter 2024 Financial ResultsSAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2024. Recent Allakos Events Initiated the randomized, double-blind, placebo-controlled Phase 1 trial of intravenous (IV) AK006 in patients with chronic spontaneous urticaria.Complet |
Can Allakos (NASDAQ:ALLK) Afford To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although... |
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy –– AK006 was well-tolerated with a favorable safety profile – SAN CARLOS, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced positive results from the single and multiple asc |
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chronic spontaneous urticaria (CSU) has been dosed in a randomized, double-blind, placebo-controlled Phase 1 trial of AK006. The Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics of AK006, and t |
Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings PredictionsDetailed Analysis of Financial Performance and Future Outlook |